Lexington, KY, United States
Lexington, KY, United States

Time filter

Source Type

Yewle J.,Vindico Pharmaceuticals | Wattamwar P.,Vindico Pharmaceuticals | Tao Z.,Massachusetts Institute of Technology | Ostertag E.M.,Vindico Pharmaceuticals | And 3 more authors.
Pharmaceutical Research | Year: 2016

Purpose: To develop a technique that maximizes the encapsulation of functional proteins within neutrally charged, fully PEGylated and nanoscale polymer vesicles (i.e., polymersomes). Methods: Three conventional vesicle formation methods were utilized for encapsulation of myoglobin (Mb) in polymersomes of varying size, PEG length, and membrane thickness. Mb concentrations were monitored by UV-Vis spectroscopy, inductively coupled plasma optical emission spectroscopy (ICP-OES) and by the bicinchoninic acid (BCA) assay. Suspensions were subject to protease treatment to differentiate the amounts of surface-associated vs. encapsulated Mb. Polymersome sizes and morphologies were monitored by dynamic light scattering (DLS) and by cryogenic transmission electron microscopy (cryo-TEM), respectively. Binding and release of oxygen were measured using a Hemeox analyzer. Results: Using the established "thin-film rehydration" and "direct hydration" methods, Mb was found to be largely surface-associated with negligible aqueous encapsulation within polymersome suspensions. Through iterative optimization, a novel "progressive saturation" technique was developed that greatly increased the final concentrations of Mb (from < 0.5 to > 2.0 mg/mL in solution), the final weight ratio of Mb-to-polymer that could be reproducibly obtained (from < 1 to > 4 w/w% Mb/polymer), as well as the overall efficiency of Mb encapsulation (from < 5 to > 90%). Stable vesicle morphologies were verified by cryo-TEM; the suspensions also displayed no signs of aggregate formation for > 2 weeks as assessed by DLS. "Progressive saturation" was further utilized for the encapsulation of a variety of other proteins, ranging in size from 17 to 450 kDa. Conclusions: Compared to established vesicle formation methods, "progressive saturation" increases the quantities of functional proteins that may be encapsulated in nanoscale polymersomes. © 2015 Springer Science+Business Media.


Romero G.,University of Kentucky | Romero G.,Vindico Pharmaceuticals | Lilly J.J.,University of Kentucky | Abraham N.S.,University of Massachusetts Amherst | And 4 more authors.
ACS Applied Materials and Interfaces | Year: 2015

Cell-based therapies are emerging as the next frontier of medicine, offering a plausible path forward in the treatment of many devastating diseases. Critically, current methods for antigen positive cell sorting lack a high throughput method for delivering ultrahigh purity populations, prohibiting the application of some cell-based therapies to widespread diseases. Here we show the first use of targeted, protective polymer coatings on cells for the high speed enrichment of cells. Individual, antigen-positive cells are coated with a biocompatible hydrogel which protects the cells from a surfactant solution, while uncoated cells are immediately lysed. After lysis, the polymer coating is removed through orthogonal photochemistry, and the isolate has >50% yield of viable cells and these cells proliferate at rates comparable to control cells. Minority cell populations are enriched from erythrocyte-depleted blood to >99% purity, whereas the entire batch process requires 1 h and <$2000 in equipment. Batch scale-up is only contingent on irradiation area for the coating photopolymerization, as surfactant-based lysis can be easily achieved on any scale. © 2015 American Chemical Society.


PubMed | Vindico Pharmaceuticals and Massachusetts Institute of Technology
Type: Journal Article | Journal: Pharmaceutical research | Year: 2016

To develop a technique that maximizes the encapsulation of functional proteins within neutrally charged, fully PEGylated and nanoscale polymer vesicles (i.e., polymersomes).Three conventional vesicle formation methods were utilized for encapsulation of myoglobin (Mb) in polymersomes of varying size, PEG length, and membrane thickness. Mb concentrations were monitored by UV-Vis spectroscopy, inductively coupled plasma optical emission spectroscopy (ICP-OES) and by the bicinchoninic acid (BCA) assay. Suspensions were subject to protease treatment to differentiate the amounts of surface-associated vs. encapsulated Mb. Polymersome sizes and morphologies were monitored by dynamic light scattering (DLS) and by cryogenic transmission electron microscopy (cryo-TEM), respectively. Binding and release of oxygen were measured using a Hemeox analyzer.Using the established thin-film rehydration and direct hydration methods, Mb was found to be largely surface-associated with negligible aqueous encapsulation within polymersome suspensions. Through iterative optimization, a novel progressive saturation technique was developed that greatly increased the final concentrations of Mb (from<0.5 to>2.0 mg/mL in solution), the final weight ratio of Mb-to-polymer that could be reproducibly obtained (from<1 to>4 w/w% Mb/polymer), as well as the overall efficiency of Mb encapsulation (from<5 to>90%). Stable vesicle morphologies were verified by cryo-TEM; the suspensions also displayed no signs of aggregate formation for>2 weeks as assessed by DLS. Progressive saturation was further utilized for the encapsulation of a variety of other proteins, ranging in size from 17 to 450 kDa.Compared to established vesicle formation methods, progressive saturation increases the quantities of functional proteins that may be encapsulated in nanoscale polymersomes.


Vindico Pharmaceuticals | Entity website

About Vindico Vindico Pharmaceuticals, based in Lexington KY, is a privately-held biotechnology company that is dedicated to the discovery, development and commercialization of highly innovative products for a wide range of diagnostic and therapeutic applications. Its product pipeline is based on a nanometer-scale particulate technology known as the polymersome ...

Loading Vindico Pharmaceuticals collaborators
Loading Vindico Pharmaceuticals collaborators